ArticleAmerican journal of cancer research2026
Drug-eluting beads transarterial chemoembolization improves tumor response and survival compared with conventional TACE in intermediate-stage hepatocellular carcinoma: a retrospective cohort study.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transarterial chemoembolization (TACE) is standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but the optimal embolization technique remains debated. This study aimed to compare effects of drug-eluting beads TACE (DEB-TACE) and conventional TACE (cTACE) on liver function and long-term survival in these patients. This retrospective investigation examined a cohort of 255 individuals diagnosed with intermediate-stage HCC, all of whom received TACE treatments at First Affiliated Hospital of Dalian Medical University between January 2019 and December 2022. Participants were categorized into cTACE group (n = 110) and DEB-TACE group (n = 145). Liver function parameters were measured at baseline, 1 week, and 1 month post-treatment. Tumor response was assessed at 1 month using mRECIST criteria. Tumor recurrence was evaluated at 3 and 6 months. Overall survival (OS) and progression-free survival (PFS) were analyzed, and adverse events were recorded. The DEB-TACE group required fewer treatment sessions (P = 0.003) and received a higher chemotherapy dose (P = 0.038). At 1 week post-treatment, DEB-TACE patients showed higher total bilirubin (TBIL, P = 0.004) and lower albumin (ALB, P = 0.012), but these differences resolved by 1 month. DEB-TACE achieved superior objective response rate (ORR, P = 0.008) and disease control rate (DCR, P = 0.019), with lower 6-month recurrence rates (P = 0.010). PFS and OS were significantly longer with DEB-TACE (P < 0.001). Multivariate analysis verified that DEB-TACE serves as an independent protective element for both PFS and OS (P < 0.001). Adverse event rates were similar between groups. DEB-TACE shows enhanced effectiveness compared to cTACE regarding tumor response, recurrence control, and long-term survival for intermediate-stage HCC, with comparable safety and only transient differences in early post-procedural liver function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.